AURKB and neoplasm: Our patient tumor sequencing data shows the overexpression of AURKA and AURKB (average Z-score = 2.33 and 2.18, respectively); the result that Panobinostat decreases AURKB shows again that it is targeting another pathway which may be playing an important role in tumor progression.